-
Mashup Score: 1NALIRIFOX Approval Revitalizes Pancreatic Cancer Management - 3 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NALIRIFOX Approval Revitalizes Pancreatic Cancer Management - 3 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0IMM-1-104 Earns FDA Fast Track Designation in Pancreatic Cancer - 3 month(s) ago
Investigators are currently evaluating treatment with IMM-1-104 in pancreatic cancer and other disease types associated with the RAS pathway as part of a phase 1/2a study.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Unlocking Insights Into Pancreatic Cancer and Cachexia - 3 month(s) ago
In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1NALIRIFOX Approval Revitalizes Pancreatic Cancer Management - 3 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX in patients with metastatic pancreatic adenocarcinoma and key data from the NAPOLI 3 trial.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
A retrospective cohort study from the Trans-Atlantic Pancreatic Surgery Consortium determined a sustained OS rate with modified FOLFIRINIX in patients with pancreatic ductal adenocarcinoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Dr Wainberg on the FDA Approval of NALIRIFOX in mPDAC - 3 month(s) ago
Zev A. Wainberg, MD, discusses the FDA approval of NALIRIFOX for patients with metastatic pancreatic ductal adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
Oncologists at Allegheny Health Network share updates on their latest approaches for optimizing surgical and systemic treatment in patients with pancreatic cancer.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Unlocking Insights Into Pancreatic Cancer and Cachexia - 4 month(s) ago
In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Unlocking Insights Into Pancreatic Cancer and Cachexia - 4 month(s) ago
In an interview with Targeted Oncology, Sanjay Goel, MD, MS, discussed the mystery of cachexia in pancreatic cancer and why it remains a challenging symptom to target.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
NALIRIFOX Approval Revitalizes Pancreatic Cancer Management @US_FDA @UCLAHealth #pancsm https://t.co/nXyMZHzUjI